Comparing PAVmed (NASDAQ:PAVM) and Insulet (NASDAQ:PODD)

PAVmed (NASDAQ:PAVM) and Insulet (NASDAQ:PODD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

Insider and Institutional Ownership

19.9% of PAVmed shares are owned by institutional investors. 11.3% of PAVmed shares are owned by insiders. Comparatively, 0.5% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

PAVmed has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Insulet has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.

Profitability

This table compares PAVmed and Insulet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PAVmed	602.97%	N/A	-92.36%
Insulet	20.19%	24.46%	8.33%

Valuation and Earnings

This table compares PAVmed and Insulet”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$4.03 million	1.81	-$64.18 million	($4.35)	-0.15
Insulet	$2.07 billion	9.14	$206.30 million	$5.79	46.58

Insulet has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for PAVmed and Insulet, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	0	0	1	1	3.50
Insulet	0	3	13	0	2.81

PAVmed currently has a consensus target price of $19.00, indicating a potential upside of 2,778.79%. Insulet has a consensus target price of $289.06, indicating a potential upside of 7.18%. Given PAVmed’s stronger consensus rating and higher probable upside, equities analysts plainly believe PAVmed is more favorable than Insulet.

Summary

Insulet beats PAVmed on 9 of the 15 factors compared between the two stocks.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.